Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line

Overview of attention for article published in Patient preference and adherence, January 2017

Altmetric Badge

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 31 Mendeley

Summary Dimensions citations

So far, Dimensions has found 15 publications that cite this research output.

15

The most recent citing publications are shown below. View all 15 publications that cite this research output on Dimensions.

Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Article in Clinical Rheumatology (September 2023)

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

Article in Musculoskeletal Care (August 2022)

Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study

Article in Frontiers in Pharmacology (November 2021)